Download PDF
Thromb Haemost 1997; 77(03): 510-515
DOI: 10.1055/s-0038-1655998
Fibrinolysis
Schattauer GmbH Stuttgart

Thrombi Formed in a Chandler Loop Mimic Human Arterial Thrombi in Structure and PAI-1 Content and Distribution

Linda A Robbie
1   The Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill, Aberdeen, Scotland, UK
2   The Department of Molecular and Cell Biology, University of Aberdeen, Foresterhill, Aberdeen, Scotland, UK
,
Simon P Young
1   The Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill, Aberdeen, Scotland, UK
,
Bruce Bennett
1   The Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill, Aberdeen, Scotland, UK
,
Nuala A Booth
2   The Department of Molecular and Cell Biology, University of Aberdeen, Foresterhill, Aberdeen, Scotland, UK
› Author Affiliations
Further Information

Publication History

Received 28 August 1996

Accepted after revision 05 November 1996

Publication Date:
11 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

We have previously shown that whole blood clots prepared under static conditions are a poor model for human thrombi formed in vivo. The most striking contrast is in the PAI-1 content, some 100 times lower in static clots than in human thrombi. This study aimed to evaluate thrombi formed in an artificial circulation (Chandler loop) using whole blood augmented with platelets. Citrated blood was recalcified and placed in tubing, which was sealed to form a closed loop and circulated. Immunohistochemical staining revealed morphology very similar to human thrombi formed in vivo, comprising dense platelet-rich heads and fibrin-rich tails. Strong positive staining for PAI-1 was observed in fibrin-rich areas of both the head and the tail. The PAI-1 content of the thrombi increased significantly on augmentation of blood with isolated platelets, and reached levels comparable with those in human thrombi. These Chandler thrombi thus provide an appropriate model system for the study of thrombus lysis, in contrast to static blood clots.

 

  • References

  • 1 Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327-333
    CrossrefPubMedGoogle Scholar
  • 2 Declerck PJ, Alessi M-C, Verstreken MV, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-225
    PubMedGoogle Scholar
  • 3 Kruithof EKO. Plasminogen activator inhibitor type 1: Biochemical, biological and clinical aspects. Fibrinolysis 1988; 2 (02) 59-70
    PubMedGoogle Scholar
  • 4 Lang I, Schleef RR. Calciu-dependent stabilization of type 1 plasminogen activator inhibitor within platelet α-granules. J Biol Chem 1996; 271: 2754-2761
    CrossrefPubMedGoogle Scholar
  • 5 Kruithof EKO, Nicoloso G, Bachmann F. Plasminogen activator inhibitor 1: development of radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-1653
    PubMedGoogle Scholar
  • 6 Robbie LA, Booth NA, Croll AM, Bennett B. The roles of α2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis. Thromb Haemost 1993; 70: 301-306
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Wagner OF, de Vries C, Hohmann C, Veerman H, Pannekoek H. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). J Clin Invest 1989; 84: 647-655
    CrossrefPubMedGoogle Scholar
  • 8 Reilly CF, Hutzelmann JE. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution. J Biol Chem 1992; 267: 7128-7135
    PubMedGoogle Scholar
  • 9 Levi M, Biemond BJ, van Zonneveld A-J, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor 1 (PAI-1) activity results in promotion of spontaneous thrombolysis and inhibition of hrombus growth in models of experimental thrombosis. Circulation 1992; 85: 305-312
    CrossrefPubMedGoogle Scholar
  • 10 Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR. Reguation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: Light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. Blood 1993; 81: 1290-1299
    PubMedGoogle Scholar
  • 11 Stringer HAR, van Swieten P, Heijnen FG, Sixma JJ, Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance: studies with thrombi generated in the Chandler loop. Arterioscler Thromb 1994; 14: 1452-1458
    CrossrefPubMedGoogle Scholar
  • 12 Sprengers ED, Akkerman JWN, Jansen BG. Blood platelet plasminogen activator inhibitor: two different pools of endothelial type plasminogen activator inhibitor in human blood. Thromb Haemost 1986; 55: 325-329
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Simpson AJ, Booth NA, Moore NR, Bennett B. The platelet and plasma pools of plasminogen activator inhibitor PAI-1 vary independently in disease. Br J Haematol 1990; 75: 543-548
    CrossrefPubMedGoogle Scholar
  • 14 Sabovic M, Lijnen HR, Keber D, Collen D. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. Thromb Haemost 1989; 62: 1083-1087
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Kunitada S, Fitzgerald GA, Fitzgerald DJ. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood 1992; 79: 1420-1427
    PubMedGoogle Scholar
  • 16 Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor 1-dependent and -independent mechanisms. Blood 1994; 83: 351-356
    PubMedGoogle Scholar
  • 17 Matsuo O, Rijken DC, Collen D. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Thromb Haemost 1981; 45: 225-229
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Loscalzo J, Vaughan DE. Tissue plasminogen activator promotes platelet disaggregation in plasma. J Clin Invest 1987; 79: 1749-1755
    CrossrefPubMedGoogle Scholar
  • 19 Jang I-K, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, May JW, Collen D. Differential sensitivity of erythrocyte-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79: 920-928
    CrossrefPubMedGoogle Scholar
  • 20 Robbie LA, Bennett B, Brown PAJ, Croll AM, Booth NA. Activators and inhibitors of the fibrinolytic system in human thrombi. Thromb Haemost 1996; 5: 127-133
    PubMedGoogle Scholar
  • 21 Legrand C, Dubemard V, Nurden AT. Characteristics of collagen-induced fibrinogen binding to human platelets. Biochim Biophys Acta 1985; 812: 802-810
    CrossrefPubMedGoogle Scholar
  • 22 Chandler AB. In vitro thrombotic coagulation of the blood. Lab Invest 1958; 7: 110-114
    PubMedGoogle Scholar
  • 23 Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford A, Stein H, Mason DY. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclo nal anti-alkaline phosphatase (APAAP complexes). JHistochem Cytochem 1984; 32: 219-229
    PubMedGoogle Scholar
  • 24 Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator (PAI-1) in tissues. J Clin Pathol 1991; 44: 139-143
    CrossrefPubMedGoogle Scholar
  • 25 MacGregor IR, Tonner AM, Mickelm LR, James K, Booth NA. Murine monoclonal antibodies against active site epitopes on human endothelial plasminogen activator inhibitor (PAI-1). Fibrinolysis 1990; 4: 27-34
    PubMedGoogle Scholar
  • 26 Tymkawycz PM, Creighton Kempsford LJ, Gaffney PJ. Generation and partial characterization of five monoclonal antibodies with high affinities for fibrin. Blood Coag Fib 1993; 4 (02) 211-221
    PubMedGoogle Scholar
  • 27 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275
    PubMedGoogle Scholar
  • 28 Peters RF, Lees CM, Mitchell KA, Tweed MF, Talbot MD, Wallis RB. The characterisation of thrombus development in an improved model of arteriovenous shunt thrombosis in the rat and the effects of recombinant desul- phatohirudin (CGP 39393), heparin and illoprost. Thromb Haemost 1991; 65: 268-274
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Handt S, Jerome WG, Braaten JV, Lewis JC, Kirkpatrick CJ, Hantgan RR. PAI-1 released from cultured human endothelial cells delays fibrinolysis and is incorporated into the developing fibrin clot. Fibrinolysis 1994; 8: 104-112
    PubMedGoogle Scholar
  • 30 Potter van Loon BJ, Rijken DC, Brommer EJP, van der Maas APC. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex vivo lysibility. Thromb Haemost 1992; 67: 101-105
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Declerck PJ, Lijnen HR, Verstreken M, Collen D. Role of α-AP in fibrin specific clot lysis with single-chain urokinase-type plasminogen activator in human plasma. Thromb Haemost 1991; 65: 394-398
    Article in Thieme ConnectPubMedGoogle Scholar